PP
AUPH icon

PDT Partners’s Aurinia Pharmaceuticals AUPH Stock Holding History

PDT Partners’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.51M Hold
265,491
– – 0.24% 136
2026
Q1 		$3.93M Hold
265,491
– – 0.23% 144
2025
Q4 		$4.23M Hold
265,491
– – 0.27% 131
2025
Q3 		$2.93M Sell
265,491
-63,210
-19% -$690K 0.19% 191
2025
Q2 		$2.78M Buy
328,701
+14,182
+5% +$114K 0.16% 224
2025
Q1 		$2.53M Buy
314,519
+12,966
+4% +$105K 0.18% 193
2024
Q4 		$2.71M Hold
301,553
– – 0.24% 142
2024
Q3 		$2.21M Buy
301,553
+130,204
+76% +$807K 0.2% 184
2024
Q2 		$978K Buy
+171,349
New +$902K 0.09% 336
2022
Q2 		– Sell
-69,917
Closed -$866K – 952
2022
Q1 		$866K Buy
+69,917
New +$1.08M 0.07% 418

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PDT Partners's AUPH Position: Q2 2026 in Review

PDT Partners held its Aurinia Pharmaceuticals (AUPH) position steady in Q2 2026 at 265,491 shares worth $4.51M. The position accounts for 0.24% of the portfolio, ranked #136.

PDT Partners first reported a position in AUPH in Q1 2022 and has held it in 10 quarters since. 282 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

  • PDT Partners held 265,491 shares of Aurinia Pharmaceuticals worth $4.51M as of Q2 2026.
  • PDT Partners left its Aurinia Pharmaceuticals share count unchanged in Q2 2026.
  • Aurinia Pharmaceuticals made up 0.24% of PDT Partners's portfolio in Q2 2026, its #136 holding.
  • PDT Partners first reported a position in Aurinia Pharmaceuticals in Q1 2022 and has held it in 10 quarters since.
  • 282 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on PDT Partners's 13F filing for Q2 2026, filed 14 Aug 2026.